Lord, Abbett & Co. LLC Protagonist Therapeutics, Inc Transaction History

Lord, Abbett & Co. LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$7.06 - $25.52 $1.95 Million - $7.04 Million	-275,787 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$23.34 - $36.08 $2.62 Million - $4.05 Million	112,123 Added 68.51%	275,787 $6.53 Million
Q4 2021 Feb 11, 2022	BUY	$17.63 - $37.1 $2.89 Million - $6.07 Million	163,664 New	163,664 $5.6 Million
Q3 2021 Nov 09, 2021	SELL	$12.95 - $49.69 $1.79 Million - $6.89 Million	-138,608 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$25.57 - $44.88 $3.54 Million - $6.22 Million	138,608 New	138,608 $6.22 Million

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.